European Organisation For Research And Treatment Of Cancer - Eortc

This study is testing if a new oral drug, darolutamide, can control prostate cancer as effectively as standard hormone therapy (ADT) over 24 weeks. It will compare how well the drug lowers PSA levels and will closely track side effects and quality of life. The goal is to see if t…

This study aimed to find the best timing for using a newer lung cancer drug called osimertinib in patients with a specific genetic change (EGFR mutation). It compared starting the drug right away versus starting an older drug first and then switching to osimertinib later, guided …

This large, late-stage trial is testing if combining a standard hormone-blocking pill (enzalutamide) with a bone-targeted radiation treatment (Ra223) works better than the pill alone for men whose prostate cancer has spread to their bones and is no longer responding to standard h…